Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Update on Pharmacotherapy for Irritable Bowel Syndrome.

Munjal A, Dedania B, Cash B.

Curr Gastroenterol Rep. 2019 Apr 25;21(6):25. doi: 10.1007/s11894-019-0692-7. Review.

PMID:
31025114
2.

Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials.

Lacy BE, Harris LA, Chang L, Lucak S, Gutman C, Dove LS, Covington PS, Lembo A.

Therap Adv Gastroenterol. 2019 Apr 15;12:1756284819841290. doi: 10.1177/1756284819841290. eCollection 2019.

3.

Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.

Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, Houghton LA, Ford AC.

Gut. 2019 Apr 17. pii: gutjnl-2018-318160. doi: 10.1136/gutjnl-2018-318160. [Epub ahead of print]

PMID:
30996042
4.

Safety of Eluxadoline Use.

Lai SW.

Am J Gastroenterol. 2019 Mar 26. doi: 10.14309/ajg.0000000000000205. [Epub ahead of print] No abstract available.

PMID:
30920418
5.

Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders?

Corsetti M, Pannemans J, Whorwell P.

F1000Res. 2019 Mar 5;8. pii: F1000 Faculty Rev-257. doi: 10.12688/f1000research.15974.1. eCollection 2019. Review.

6.

Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review.

Khetpal N, Yadav L, Khalid S, Kumar R.

Cureus. 2018 Dec 18;10(12):e3747. doi: 10.7759/cureus.3747.

7.

Eluxadoline.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

8.

Letter: eluxadoline-associated acute pancreatitis-myth or reality?

Garcia-Gonzalez F, Faghih M, Singh V.

Aliment Pharmacol Ther. 2018 Aug;48(4):490-491. doi: 10.1111/apt.14846. No abstract available.

PMID:
30588698
9.

Letter: eluxadoline-associated acute pancreatitis-myth or reality? Authors' reply.

Harinstein L, Wu E, Brinker A.

Aliment Pharmacol Ther. 2018 Aug;48(4):491-492. doi: 10.1111/apt.14851. No abstract available.

PMID:
30588693
10.

High sensitive LC-MS/MS method for estimation of eluxadoline in human plasma and its application to pharmacokinetic study.

Dodda S, Makula A, Polagani SR, Kandhagatla RN.

J Pharm Biomed Anal. 2019 Feb 20;165:65-72. doi: 10.1016/j.jpba.2018.11.056. Epub 2018 Nov 24.

PMID:
30502553
11.

Irritable Bowel Syndrome: What Treatments Really Work.

Alammar N, Stein E.

Med Clin North Am. 2019 Jan;103(1):137-152. doi: 10.1016/j.mcna.2018.08.006. Review.

PMID:
30466670
12.

Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.

Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL.

Curr Med Res Opin. 2019 Mar;35(3):461-472. doi: 10.1080/03007995.2018.1533456. Epub 2018 Nov 22.

PMID:
30293448
13.
14.

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea.

Abel JL, Carson RT, Andrae DA.

Qual Life Res. 2019 Feb;28(2):369-377. doi: 10.1007/s11136-018-2008-z. Epub 2018 Sep 28.

15.

Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.

Lacy BE.

Aliment Pharmacol Ther. 2018 Oct;48(8):817-830. doi: 10.1111/apt.14948. Epub 2018 Sep 7. Review.

PMID:
30194692
16.

Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?

Pannemans J, Corsetti M.

Curr Opin Pharmacol. 2018 Dec;43:53-58. doi: 10.1016/j.coph.2018.08.008. Epub 2018 Sep 3. Review.

PMID:
30189347
17.

Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis.

Zhu L, Ma Y, Ye S, Shu Z.

Evid Based Complement Alternat Med. 2018 May 27;2018:2890465. doi: 10.1155/2018/2890465. eCollection 2018. Review.

18.

New treatments and therapeutic targets for IBS and other functional bowel disorders.

Simrén M, Tack J.

Nat Rev Gastroenterol Hepatol. 2018 Oct;15(10):589-605. doi: 10.1038/s41575-018-0034-5. Review.

PMID:
29930260
19.

Sphincter of Oddi dysfunction: sphincter of Oddi dysfunction or discordance? What is the state of the art in 2018?

Hyun JJ, Kozarek RA.

Curr Opin Gastroenterol. 2018 Sep;34(5):282-287. doi: 10.1097/MOG.0000000000000455. Review.

PMID:
29916850
20.

Evaluation of Eluxadoline Effect on Cardiac Repolarization.

Bonifacio L, Hunt TL, McIntyre G, Dove LS, Covington PS.

Clin Pharmacol Drug Dev. 2018 Sep;7(7):727-736. doi: 10.1002/cpdd.453. Epub 2018 Apr 16.

Supplemental Content

Loading ...
Support Center